Physician profile
Courtney Younglove
NPI 1013991413
$6,565.14
in general payments reported to CMS, 2019-2025
11 companies · $78.61 in 2025
The $78.61 reported for 2025 was less than what a typical Obesity Medicine (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $97.38).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $204 · 2022: $76.39 · 2023: $5,876 · 2024: $112 · 2025: $78.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,550 · Travel and Lodging: $1,024 · Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,550.00 |
| Travel and Lodging | $1,023.91 |
| Food and Beverage | $492.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,778.47 | 2023 | |
| Novo Nordisk INC | $318.55 | 2021-2025 | |
| Rhythm Pharmaceuticals, INC. | $152.36 | 2021-2022 | |
| Vivus LLC | $97.14 | 2023 | Qsymia |
| Merck Sharp & Dohme LLC | $62.29 | 2019 | |
| Pfizer INC. | $45.73 | 2019 | |
| Abbvie INC. | $42.39 | 2019 | |
| Olympus America INC. | $23.63 | 2019 | |
| Coopersurgical, INC. | $20.81 | 2019 | |
| Therapeuticsmd, INC. | $12.71 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Younglove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.